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NMR detection in bioﬂuid extracts at sub-μM
concentrations via para-H2 induced
hyperpolarization†
I. Reile, N. Eshuis, N. K. J. Hermkens, B. J. A. van Weerdenburg, M. C. Feiters,
F. P. J. T. Rutjes and M. Tessari*
NMR spectroscopy is one of the most powerful techniques to sim-
ultaneously obtain qualitative and quantitative information in
chemical analysis. Despite its versatility, the applications of NMR in
the study of bioﬂuids are often limited by the insensitivity of the
technique, further aggravated by the poor signal dispersion in the
1H spectra. Recent advances in para-H2 induced hyperpolarization
have proven to address both these limitations for speciﬁc classes
of compounds. Herein, this approach is for the ﬁrst time applied
for quantitative determination in bioﬂuid extracts. We demonstrate
that a combination of solid phase extraction, para-hydrogen
induced hyperpolarization and selective NMR detection quickly
reveals a doping substance, nikethamide, at sub-μM concen-
trations in urine. We suggest that this method can be further opti-
mized for the detection of diﬀerent analytes in various bioﬂuids,
anticipating a wider application of hyperpolarized NMR in meta-
bolomics and pharmacokinetics studies in the near future.
Introduction
Analysis of biofluids is a well-established tool in various fields of
biomedical and biochemical research, ranging from routine diag-
nostics to metabolomics,1 biomarker discovery2 and drug metab-
olism.3 Studies of serum, plasma, sweat, saliva, cerebrospinal
fluid and urine have been conducted,4 wherein each oﬀers infor-
mation on diﬀerent metabolic processes. Urine is often the bio-
fluid of choice to obtain qualitative and quantitative data on an
individual’s metabolic state and health condition, since it is rich
in diagnostic information and can be collected noninvasively.5
At the outset, nuclear magnetic resonance spectroscopy
(NMR) is a powerful technique for the analysis of urine, as it
oﬀers structural information on analytes and is quantitative,
non-specific and non-destructive.4 NMR analysis of any
complex mixture or biofluid is, however, limited by the
inherent low sensitivity of the technique and by spectral con-
gestion. Urine is known to contain over 3000 metabolites in a
wide concentration range (∼106),6 causing signal overlap of
dilute components, generally hidden by more abundant com-
ponents.1 To a certain degree, these limitations can be alle-
viated by accumulating more scans and performing complex
multi-dimensional NMR experiments. Unfortunately both
come at the cost of noticeably increased measurement times
and hence limit the throughput, often rendering NMR detec-
tion of dilute analytes impractical or even impossible.
For specific classes of compounds both the sensitivity and
the overlap issues can be addressed at once, following an
approach based on chemoselective signal enhancement.7 Such
a technique has been demonstrated for nitrogenous hetero-
cyclic compounds by using para-hydrogen (p-H2) induced
hyperpolarization in a Signal Amplification By Reversible
Exchange (SABRE)8 experiment. Since urine is known to be
relatively abundant in nitrogen rich metabolites that are elimi-
nated from the blood stream and excreted renally,5,6 SABRE
could potentially selectively reveal these analytes. This
approach would also allow the detection of a variety of drugs
and metabolites thereof in urine since heteroaromatic
scaﬀolds are ubiquitous in drug development,9 as witnessed
by the fact that a quarter of the 200 most sold drugs contain
nitrogenous aromatic building blocks.10
SABRE8 relies on the reversible chemoselective binding of
analytes to an organometallic iridium complex 1 (Scheme 1)
that serves as a polarization transfer catalyst at a low magnetic
field. During the lifetime of 1, conversion of the spin order of
p-H2 to
1H nuclear hyperpolarization of the bound analyte
occurs. Dissociation of the complex results in hyperpolarized
analyte molecules in solution, providing NMR signal enhance-
ments up to three orders of magnitude. A recent high-field
development allows detection of hydride-analyte correlations in
112 in a 2D continuous hyperpolarization experiment, providing
additional spectral dispersion. Either approach allows fast 1H
NMR detection in mixtures at sub-μM concentrations.12,13
†Electronic supplementary information (ESI) available: Information on chemi-
cals and materials, urine sample handling, NMR sample preparation and experi-
ment, repeatability and calibration. See DOI: 10.1039/c6an00804f
Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135,
6525 AJ Nijmegen, The Netherlands. E-mail: m.tessari@science.ru.nl;
Tel: +31 24 3652113
This journal is © The Royal Society of Chemistry 2016 Analyst, 2016, 141, 4001–4005 | 4001
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
M
ay
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
4/
08
/2
01
6 
15
:2
5:
39
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal  | View Issue
Urine, however, is inherently aqueous, an environment in
which SABRE catalysts perform poorly.14,15 Water compatible
catalysts are being developed, but their hyperpolarization per-
formance falls short of similar systems in organic solvents.14,16
In addition, urine contains a variety of salts, biopolymers,
urea, etc.,6 the interactions of which with the Ir-catalysts are
expected to negatively interfere with SABRE. As a matter of
fact, previous attempts to perform SABRE directly in a biofluid
have seen limited success only, reporting sample coagulation
and strongly reduced signal enhancements.15 Here, we demon-
strate that these issues can be overcome so that SABRE-based
hyperpolarization can be applied to urine for the detection
and quantification of specific dilute compounds. A protocol of
three layers of filtering was developed to render urine amend-
able to hyperpolarization and to resolve low-μM spectral infor-
mation from its complex biofluid matrix (Scheme 2).
Experimental
Sample preparation
Urine samples were stored at −20 °C in 12 mL aliquots and
thawed over a room temperature water bath prior to use. The
pH of samples was adjusted to 7.5 with dropwise addition of
1 M NaOH and the samples were centrifuged at room tempera-
ture for 15 min (3750 RCF) to remove the sediment. Details of
sample collection and storage are available in the ESI.†
Solid phase extraction (SPE)
Cartridges (Waters HLB, 6 mL, 200 mg) were activated with
methanol (3 mL), conditioned with water (3 mL) and loaded
with urine (5 mL). A steady flow rate of 1 mL min−1 was main-
tained by using an electronically controlled syringe pump. The
cartridge was washed with water (3 mL) and dried with a flow
of N2 (2 L min
−1) over 30 min. Methanol-d4 (1100 μL) was
added and allowed to elute by gravity before forcing the
residual extract out with a syringe, yielding approx. 650 μL of
extract which was used without further treatment. The rest of
the solvent is absorbed by the sorbent. All the studied analytes
are released into 650 μL of extract (elution curves in Fig. S1†).
Each extract was weighed to obtain precise ‘per sample’ con-
centration factors.
NMR experiment
A solution consisting of 4.8 mM of the catalyst precursor
[Ir(Cl)(COD)(IMes)] and 72 mM of mtz (1-methyl-1,2,3-triazole)
co-substrate in methanol-d4 (130 mg) was weighed into a
5 mm medium wall Wilmad® quick pressure valve NMR tube.
The precursor was pressurized under 5 bar of H2, shaken vigor-
ously and allowed to hydrogenate at room temperature for 2 h
to generate a solution of the active [Ir(H)2(IMes)(mtz)3]
+ cata-
lyst. 390 mg of extract was added to the NMR tube and 51%
p-H2 was bubbled through the sample,
12 followed by the NMR
experiment on 500 or 600 MHz spectrometers equipped with a
cryoprobe.
Repeatability and calibration
Urine samples from 5 volunteers were gravimetrically spiked to
2 µM of dENA and mENA and subjected to SPE and NMR.
Each extract was analyzed 3 times and the integrals were aver-
aged. The reported repeatability is presented as the RSD value
across 5 samples. The linear response of the method was
demonstrated by a calibration experiment where identical
urine samples were gravimetrically spiked to increasing con-
centrations of dENA and mENA (0.5, 2.0, 5.0, 10.0 and
25.0 μM) and subjected to SPE and NMR. All the extracts were
analyzed three times and the integrals were averaged. The cali-
bration curve (Fig. 5B) was calculated by linear regression ana-
lysis of experimental data. Further details are available in the
ESI.†
Results and discussion
The 1st layer of filtering consists of removing salts, urea and
macromolecular aggregates from urine and changing the
solvent to maximize the catalyst performance, all of which are
achieved by Solid Phase Extraction (SPE). Screening of a variety
of commercially available SPE cartridges, diﬀering by their
selectivity and the retention mechanism,17 and optimization
of the extraction protocol was achieved by targeting endoge-
nous nicotinamide (NA). This compound occurs in urine at
low-μM concentrations6 and can be detected by NMR using
SABRE.8,12,13,16,18 The SPE protocol optimized for NA was
expected to extract also other nitrogenous heterocyclic com-
pounds. 7.7-fold sample concentration was achieved by SPE of
5 mL of urine, followed by elution into 650 μL of methanol-d4,
a catalyst compatible solvent. The obtained mixture is still
remarkably complex, as evidenced by comparison with the
original urine NMR 1H spectrum (Fig. 1).
Selective NMR detection of target analytes in SPE extracts is
achieved by chemoselective catalyst binding in the 2nd layer of
Scheme 2 Layers of sample, chemoselective and spectral ﬁltering.
Scheme 1 Polarization transfer in SABRE. A co-substrate (mtz,
1-methyl-1,2,3-triazole) is introduced for analyte hyperpolarization in
the low-μM regime.11
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filtering. Following the addition of p-H2 and an iridium cata-
lyst, nitrogenous heterocyclic compounds in the SPE extract
will specifically bind to the metal. This association is revealed
by a pair of enhanced hydride NMR signals for each bound
analyte.19 The obtained 1H spectrum (Fig. 2) contains exclu-
sively enhanced signals from complexes 1 and is free from
background contributions, addressing both the NMR sensi-
tivity issues and the spectral overlap caused by the complex
urine matrix. This hydride spectrum indicates the presence of
dozens of target analytes; signals generated by the association
of NA to the Ir-complex could be straightforwardly identified
by spiking the NMR sample. In comparison with the NA peak
intensity, several signals in Fig. 2 can be safely assumed to
correspond to sub-μM analytes. Yet, thorough signal identifi-
cation is still hampered by spectral overlap.
Improved spectral dispersion is obtained by polarization
transfer from the enhanced hydrides to the analyte protons
(Fig. 3A) via long-range couplings in complexes 1.12 This
helps in resolving hydride signal overlap in a 2D correlation
Fig. 1 (A) 1H spectrum of human urine; (B) SPE extract from 5 mL of the same urine, concentrated into 650 μL of methanol-d4.
Fig. 2 Hyperpolarized hydride signals of complexes 1 in SPE extract of
urine (51% p-H2, 1.2 mM catalyst, 18 mM mtz). The spectrum was
acquired using a SEPP pulse scheme (see the ESI†).20,21
Fig. 3 (A) Pulse sequence for acquisition of the hyperpolarized
hydride-analyte 2D correlation spectra. Further details are available in
ref. 12. Polarization transfer in complex 1 of NA is indicated by red
arrows; (B) hydride-analyte 2D correlation spectrum of urine SPE
extract; (C) ﬁltered 1D spectrum: a 175 Hz bandwidth selective excitation
pulse at −22.96 ppm (see the vertical axis, (B)) also excites hydride reso-
nances at −23.10 ppm, giving rise to four additional hyperpolarized
signals.
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spectrum, providing access to low-μM spectral information for
individual analytes (Fig. 3B). Such a 2D spectrum was acquired
in 25 min and provides suﬃcient resolution for quantitative
determination of low-μM metabolites that can be identified by
spiking. Significant gains can be, however, obtained in
throughput if selective detection of specific compounds is
desired. In a 3rd layer of filtering the hydride resonance of the
NA complex at −22.96 ppm (Fig. 2) is selectively excited with
a narrow bandwidth pulse and the magnetization is
transferred in a 1D version of the same experiment (Fig. 3A).12
The resulting 1D spectrum displayed in Fig. 3C was acquired
in four minutes, providing spectrally filtered information on
the analytes of interest.
In order to verify the repeatability as well as the quantitative
character of the measurements, we applied the proposed
method for the detection of non-endogenous derivatives of NA
in urine. For this we selected N,N-diethylnicotinamide
(nikethamide, dENA), a respiratory stimulant that aﬀects the
central nervous and cardiovascular systems and is banned by
the World Anti-Doping Agency (WADA).22 Abuse of dENA may
also be detected by its metabolite N-ethylnicotinamide
(mENA), as neither occur endogenously.23 Urine samples were
spiked with both the compounds and subjected to the method
herein. The result after the three layers of filtering described
above is illustrated in the 1D spectrum in Fig. 4, in which NA,
dENA and mENA each have one baseline resolved peak.
The repeatability of the method was investigated by
collecting urine samples from five individuals and spiking
them to 2 μM of dENA and mENA. Good repeatability was
found, as indicated by the RSD of 5.7% and 12.0% for dENA
and mENA, respectively.
The quantitative character of the proposed approach was
further tested by spiking five identical urine samples with
increasing concentrations of dENA and mENA. We have pre-
viously demonstrated the linear dependence of the NMR
signal integrals and concentration in hyperpolarized
samples.12,13 Such a linear dependence also holds in the
present case, as illustrated by the calibration curves displayed
in Fig. 5. The lowest concentration used for calibration (0.5 μM
in urine) yields a S : N ratio of 6 after 64 scans (4 min),
meeting the WADA requirements for stimulant detection;24
accumulating more scans or using fully enriched p-H2 would
reduce the detection limit further. These calibration curves
allow the correlation of peak integrals with analyte concen-
trations in urine and, therefore, form the basis for the appli-
cation of this approach in quantitative metabolite and drug
analysis.
Conclusions
By combining a SPE-based sample preparation procedure with
p-H2 induced hyperpolarization we have achieved selective
NMR detection of a specific class of metabolites in a complex
mixture of biological origin. SPE forms the first of three selec-
tion layers, allows enrichment of the sample in the com-
pounds of interest and renders urine compatible with SABRE
catalyst systems. The analyte specificity of the signal enhance-
ment in the second layer is utilized for the chemoselective
hyperpolarization, allowing the amplification of the desired
Fig. 4 1D selective excitation spectrum of urine SPE extract after
spiking urine with 2 μM of dENA and mENA. 8.84 ppm and 9.03 ppm
peaks were used for quantiﬁcation. The spectra were recorded with 175
Hz selective excitation at −22.96 ppm, where the hydride signals of NA,
dENA and mENA overlap.
Fig. 5 (A) NMR response at diﬀerent analyte concentrations; (B) cali-
bration curve for dENA and mENA in urine. Due to the overlap with NA
at >10 μM, mENA calibration was not attempted at higher concen-
trations. Error bars represent standard errors of three repeated
measurements.
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signals and ignoring the otherwise dominating metabolic
background. The method allows to explore low-μM concen-
trations of target analytes in urine, as quantitatively demon-
strated for a doping substance, nikethamide, and its
metabolite. Note that the sensitivity achieved herein can be
further increased threefold by using fully enriched p-H2. The
same method can be applied to diﬀerent biofluids, provided a
proper choice of SPE sorbents and extraction conditions is
made for the targeted analytes. The collection of known
SABRE substrates includes other drugs (nicotine and
harmine,25 pyrazinamide and isoniazid26) as well as adenine
and adenosine,15 tagged oligopeptides,27 nitriles28 and various
heteroaromatic compounds.12,13,18,29 Since this list is continu-
ously growing, we can foresee a wider application of p-H2
hyperpolarization in NMR applications in biochemistry,
including possible future application in metabolomics and
pharmacokinetics analysis.
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